A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

Healthy Volunteers Clinical Trial

Official title:

A Randomized, Open-label, Single-dose, 4-period, 4--sequence, Crossover Phase I Relative Bioavailability Study Comparing Crystalline Formulation Tablet Versus Reference Amorphous Formulation Tablet of Rilzabrutinib (SAR444671) in Fasted and Fed Conditions in Healthy Male and Female Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06342700
• Other study ID #: PKM18138
• Secondary ID: U1111-1299-1906
• Status: Completed
• Phase: Phase 1
• Start date: March 25, 2024
• Est. completion date: April 23, 2024

Study information

• Verified date: April 2024
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a cross-over, Phase 1, 4-arm study. The purpose of this study is to measure the relative bioavailability and food effect of crystalline formulation rilzabrutinib and amorphous formulation rilzabrutinib in healthy male and female participants aged 18 to 55 years of age. The total study duration per participant is expected to be up to 36 days, including: - Screening: up to 4 weeks - Treatment periods: once successfully screened, enrolled participants will be randomized to 1 of 4 treatment sequences with 4 single dose treatment periods. - Washout: One day washout is planned after each treatment period hence providing 2 days between doses. - Safety follow-up: participants will be asked to participate in an end-of-study safety assessment upon discharge from the clinical study unit, ie, on Day 8 of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: April 23, 2024
• Est. primary completion date: April 23, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive
• Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participant. Hepatic transaminases (aspartate aminotransferase, alanine aminotransferase) should not exceed 1.25 × the upper laboratory norm (ULN); total bilirubin should not exceed 1 × ULN
• Willing to abstain from using tobacco or nicotine-containing products or consuming alcohol from check-in (Day -1) until discharge at end-of-study visit
• Willing to abstain from taking any prescription drugs, dietary supplements, or non-prescription drugs within 14 days or 5 half-lives, whichever, is longer, prior to the first dose of study drug through the follow-up phone call. Use of hormonal contraception and aspirin (at doses of =2000 mg/day) or ibuprofen (at doses of =1200 mg/day) are allowed prior to and during the study
• Negative urine drug/alcohol testing at screening and check-in (Day -1). Screening urine drug/alcohol testing may be repeated once if deemed appropriate by the site Investigator
• Willing to abstain from consuming grapefruit, star fruit, or Seville orange-containing products from 14 days prior to first dose of study drug until discharge from the clinical study unit

Exclusion Criteria:

• Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), infectious disease, or signs of acute illness
• Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation [ECMO], mechanically ventilated)
• Participant has a positive test result for SARS-CoV-2 (measured via Real-time Reverse Transcriptase Polymerase Chain Reaction [RT-PCR] or Rapid Antigen Test [RAT])
• Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month)
• Blood donation, any volume, within 1 month before inclusion
• Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure <30 mmHg within 3 minutes when changing from supine to standing position
• Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. Participants with known hypersensitivity to any component of the IMP formulation or allergic disease diagnosed and treated by a physician
• History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis)
• Regular intake of nicotine (via patch, smoking, vaping or other forms) more than 10 mg per day (based on the average nicotine content of 10-12 mg of nicotine per cigarette and inhalation of up to 2 mg of nicotine per cigarette), and unable to stop smoking during the study (occasional smoker can be enrolled)
• Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
• If female, pregnancy (defined as positive ß-HCG blood test), or breast-feeding
• Any medication (including St John's Wort or ginseng) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of aspirin/ibuprofen, hormonal contraception, and menopausal hormone replacement therapy
• Any vaccination within the last 28 days and any biologics (antibody or its

derivatives) given within 4 months before inclusion:

• Non-live vaccines, including COVID-19: last administration of a vaccine within 4 weeks before randomization
• Live vaccines: last administration of a vaccine within 3 months before randomization
• Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
• Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates)
• Positive alcohol breath or alcohol urine test
• Positive pregnancy test
• Gilbert's Syndrome The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Autoimmune Diseases
• Autoimmune Disorder
• Healthy Volunteers

Intervention

Drug:
• Rilzabrutinib crystalline form
Pharmaceutical form:Film coated tablet Route of administration:Oral
• Rilzabrutinib amorphous form
Pharmaceutical form:Film coated tablet Route of administration:Oral

Locations

Country	Name	City	State
United States	Nucleus Network Site Number : 8400001	Saint Paul	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fasted state	Cmax: maximum plasma concentration	Day 1 to Day 8
Primary	Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fasted state	AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration	Day 1 to Day 8
Primary	Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fasted state	AUC: area under the plasma concentration versus time curve extrapolated to infinity	Day 1 to Day 8
Secondary	Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fed state	Cmax: maximum plasma concentration	Day 1 to Day 8
Secondary	Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fed state	AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration	Day 1 to Day 8
Secondary	Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fed state	AUC: area under the plasma concentration versus time curve extrapolated to infinity	Day 1 to Day 8
Secondary	Food effects as assessed by rilzabrutinib Cmax following administration of the test and reference formulations under the fed versus fasted state	Cmax: maximum plasma concentration	Day 1 to Day 8
Secondary	Food effects as assessed by rilzabrutinib AUClast following administration of the test and reference formulations under the fed versus fasted state	AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration	Day 1 to Day 8
Secondary	Food effects as assessed by rilzabrutinib AUC following administration of the test and reference formulations under the fed versus fasted state	AUC: area under the plasma concentration versus time curve extrapolated to infinity	Day 1 to Day 8
Secondary	Number of participants with adverse events, treatment-emergent adverse events, serious adverse events and adverse events of special interest		Day 1 to Day 8